Neurosense Therapeutics Ltd. (NRSN) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
NeuroSense Therapeutics has announced promising results from its PARADIGM study, showing that its drug PrimeC significantly slows disease progression and boosts survival rates in ALS patients. The study suggests a 33% improvement in disease progression and a 58% increase in survival rates for those starting treatment with PrimeC, potentially redefining ALS care standards.
For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.
